Key facts
- This page summarizes Daniel B. Soland's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2022, 20:21.
Daniel B. Soland - 07 Jun 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- Director
- Issuer ticker
- ACAD
- Reported as of
- 07 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2022, 20:21:40 UTC
- Prior SEC filing
- 04 Apr 2022
- Next SEC filing
- 07 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Austin D. Kim, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Daniel B. Soland filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 09 Jun 2022.
Change
- Previous filing in this sequence was filed on 04 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Director Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +14,368
- Change %
- Price
- $0.000000
- Shares after
- 14,368
- Date
- 07 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,368
- Exercise price
- $18.27
- Footnotes
- F1
ACAD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +8,552
- Change %
- Price
- $0.000000
- Shares after
- 8,552
- Date
- 07 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,552
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
Footnote F3
The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date.